BRIEF published on 11/11/2025 at 07:29, 23 days 22 hours ago Medios AG Reports Robust Earnings Growth in Early 2025 EBITDA Revenue Growth Financial Performance Pharmaceuticals Medios AG
PRESS RELEASE published on 11/11/2025 at 07:24, 23 days 23 hours ago Medios AG achieves strong growth in earnings and profit margin in the first nine months of 2025 Medios AG achieves 9.2% revenue growth and 26.1% increase in EBITDA pre1 in the first nine months of 2025. New CEO appointed. Outlook confirmed. Details in press release EBITDA Revenue Growth CEO Appointment Medios AG 2025 Outlook
BRIEF published on 11/03/2025 at 10:02, 1 month 1 day ago Thomas Meier Appointed CEO of Medios AG Growth Strategy CEO Appointment Medios AG Specialty Pharma Thomas Meier
PRESS RELEASE published on 11/03/2025 at 09:57, 1 month 1 day ago Thomas Meier becomes new CEO of Medios AG Thomas Meier appointed as new CEO of Medios AG effective February 1, 2026, succeeding Matthias Gaertner. Meier's past roles include CEO of Bachem Holding AG. Medios AG aims for further growth under his leadership CEO Appointment Medios AG Specialty Pharma Thomas Meier Bachem Holding AG
BRIEF published on 10/24/2025 at 11:09, 1 month 11 days ago Medios AG: Reallocation of Bencis Shares Medios AG Specialty Pharma Share Reallocation Bencis Capital Partners Janus Henderson Group
PRESS RELEASE published on 10/24/2025 at 11:04, 1 month 11 days ago Medios AG: Reallocation of Bencis shares Medios AG announces reallocation of Bencis shares to Janus Henderson, representing approximately 6.7% of share capital. Bencis sold shares acquired in 2024 through capital increase related to Ceban Pharmaceuticals B.V Janus Henderson Medios AG Specialty Pharma Bencis Shares Individualized Medicine
BRIEF published on 08/13/2025 at 07:42, 3 months 22 days ago Medios AG Reports Strong Growth in H1 2025 Revenue Growth Medios AG EBITDA Increase H1 2025 Pharmaceutical Segments
PRESS RELEASE published on 08/13/2025 at 07:37, 3 months 22 days ago Medios accelerates growth in the first half of 2025 and significantly increases earnings Medios accelerates growth in the first half of 2025, with revenue up by 9.3% to €991.7 million and EBITDA significantly increasing by 48.8%. Successful share buyback. Positive outlook for 2025 EBITDA Revenue Outlook Growth Medios
BRIEF published on 07/11/2025 at 10:00, 4 months 24 days ago Medios Completes Share Buyback Offer Share Buyback Investor Relations Medios AG Public Offer Capital Acquisition
PRESS RELEASE published on 07/11/2025 at 09:55, 4 months 24 days ago Medios successfully completes public share buyback offer Medios AG successfully completes public share buyback offer, acquiring 3.92% of its share capital. Important dates for Medios Group in 2025 included Share Buyback Financial Report Medios AG Public Offer Specialty Pharma
Published on 12/05/2025 at 02:35, 3 hours 53 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 28 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 23 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 28 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 57 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 37 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 2 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 13 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 17 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 28 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 43 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 43 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 27 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
